Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed ductal cell or undifferentiated adenocarcinoma of the pancreas * Previously untreated metastatic disease * No islet cell or acinar cell carcinoma or cystadenocarcinoma * No invasion of adjacent organs (i.e., duodenum or stomach) or major blood vessels ( i.e., superior mesenteric artery or celiac artery) * No CNS metastasis PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 6 months Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10.0 g/dL * No bleeding diathesis or uncontrolled coagulopathy * No bleeding events within the past 6 months Hepatic * Bilirubin ≤ 2 times upper limit of normal (ULN) (stenting allowed) * AST ≤ 5 times ULN * No esophageal varices Renal * Creatinine ≤ 2 times ULN * Proteinuria \< 1+ by dipstick or urinalysis OR * Protein \< 1 g/24-hr urine collection * No nephrotic syndrome Cardiovascular * No New York Heart Association class II-IV congestive heart failure * No symptomatic, unstable angina, or coronary artery disease * No uncontrolled cardiac arrhythmias * No myocardial infarction within the past 6 months * No uncontrolled hypertension * No history of cerebrovascular events * No clinically significant peripheral arterial disease * No other clinically significant cardiac disease Pulmonary * No hemoptysis within the past 6 months Immunologic * No history of allergy or hypersensitivity to bevacizumab, oxaliplatin, or gemcitabine * No hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No known allergy to other platinum compounds * No ongoing or active infection Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * No serious, non-healing wound, ulcer, or bone fracture * No pre-existing peripheral neuropathy \> grade 1 * No other malignancy within the past 5 years except basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or prostate cancer with a Gleason score \< 7 * No psychiatric illness or social situation that would preclude study compliance * No other uncontrolled illness * No gastrointestinal bleeding within the past 6 months * No unresolved physical trauma within the past 4 weeks PRIOR CONCURRENT THERAPY: Biologic therapy * More than 4 months since prior immunotherapy or biologic therapy * No prior adjuvant bevacizumab * No concurrent immunotherapy * No concurrent colony-stimulating factors during the first course of study therapy Chemotherapy * Recovered from prior chemotherapy * More than 4 months since prior adjuvant chemotherapy for completely resected disease * At least 4 months since prior chemoradiotherapy for locally advanced disease * More than 4 months since prior gemcitabine as a radiosensitizer or as maintenance therapy * No prior cytotoxic chemotherapy for metastatic disease * No prior adjuvant oxaliplatin * No other concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * See Chemotherapy * More than 4 months since prior radiotherapy * No prior radiotherapy to \> 25% of bone marrow * No prior radiotherapy to sole site of measurable disease unless there is radiologically confirmed progression of the irradiated tumor * No concurrent radiotherapy Surgery * More than 4 weeks since prior major surgery or trauma and recovered * No concurrent surgery Other * More than 2 weeks since prior and no concurrent thrombolytic agents * Anticoagulation therapy with warfarin or low molecular weight heparin is allowed provided the following criteria are met: * At least 2 weeks at a stable dose * INR 2-3 * No active bleeding or pathologic condition that confers a high risk of bleeding (e.g., tumor involving major vessels or known varices) * No recent or concurrent participation in another study of experimental drugs